Skip to main content

AS/Spondyloarthritis

      RT @uptoTate: Dr. M. Dubreuil shares a beautiful slide describing the asynchrony between the goal and the reality in the
      Dr. M. Dubreuil shares a beautiful slide describing the asynchrony between the goal and the reality in the classification of axSpA. Do you think it’s time to change our nomenclature and classification criteria? #ACR20 @RheumNow https://t.co/YJcvLKnyFy
      RT @uptoTate: Dr. J. Kay reviews ICD11 classification codes for medical claims for diagnosing SpA which reviews ASAS cri
      Dr. J. Kay reviews ICD11 classification codes for medical claims for diagnosing SpA which reviews ASAS criteria. This likely won’t be adopted in the US for several years. #ACR20 ⁦@RheumNow⁩ https://t.co/oDhs1EHSTP
      RT @uptoTate: Do you know Walter Bauer, MD #ACR20? Well, I didn't either! Dr. M. Weinblatt taught me that Dr. Bauer was
      Do you know Walter Bauer, MD #ACR20? Well, I didn't either! Dr. M. Weinblatt taught me that Dr. Bauer was an important US rheumatologist who did NOT believe AS was a separate disease entity from RA! It wasn't until his death that the college recognized both separately! @RheumNow
      RT @doctorRBC: Gender differences in Axial Spondyloarthritis patientsPooled data from 3 Ixekizumab studiesWomen:1⃣o

      Gender differences in Axial Spondyloarthritis patients Pooled data from 3 Ixekizumab studies Women: 1⃣older at disease onset (30 vs. 26) 2⃣Longer symptom duration (17.8 yrs vs. 16.7 yrs) 3⃣More peripheral joint pain and lower HLA-B27 @RheumNow #ACR20 Abs#0876 https://t.co/qGHXApi0Ko

      RT @Janetbirdope: Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some min
      4 years ago

      Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ

      RT @uptoTate: MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (dom
      MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (domain?) response to TNFi vs IL17i. Dr. J. Ermann #ACR20 @RheumNow #ACRbest https://t.co/0ZcEIvkuMj
      RT @synovialjoints: Which Axial SpA outcome score do you use in clinic as a target to achieve? @RheumNow #ACR20
      Which Axial SpA outcome score do you use in clinic as a target to achieve? @RheumNow #ACR20